Literature DB >> 22206666

The sclerostin-bone protein interactome.

Hemamalini Devarajan-Ketha1, Theodore A Craig, Benjamin J Madden, H Robert Bergen, Rajiv Kumar.   

Abstract

The secreted glycoprotein, sclerostin alters bone formation. To gain insights into the mechanism of action of sclerostin, we examined the interactions of sclerostin with bone proteins using a sclerostin affinity capture technique. Proteins from decalcified rat bone were captured on a sclerostin-maltose binding protein (MBP) amylose column, or on a MBP amylose column. The columns were extensively washed with low ionic strength buffer, and bound proteins were eluted with buffer containing 1M sodium chloride. Eluted proteins were separated by denaturing sodium-dodecyl sulfate gel electrophoresis and were identified by mass spectrometry. Several previously unidentified full-length sclerostin-interacting proteins such as alkaline phosphatase, carbonic anhydrase, gremlin-1, fetuin A, midkine, annexin A1 and A2, and collagen α1, which have established roles in bone formation or resorption processes, were bound to the sclerostin-MBP amylose resin but not to the MBP amylose resin. Other full-length sclerostin-interacting proteins such as casein kinase II and secreted frizzled related protein 4 that modulate Wnt signaling were identified. Several peptides derived from proteins such as Phex, asporin and follistatin that regulate bone metabolism also bound sclerostin. Sclerostin interacts with multiple proteins that alter bone formation and resorption and is likely to function by altering several biologically relevant pathways in bone.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206666      PMCID: PMC3259242          DOI: 10.1016/j.bbrc.2011.12.048

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  52 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth.

Authors:  Miki Shitashige; Reiko Satow; Takafumi Jigami; Kazunori Aoki; Kazufumi Honda; Tatsuhiro Shibata; Masaya Ono; Setsuo Hirohashi; Tesshi Yamada
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

3.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

4.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

Review 5.  The roles of annexins and alkaline phosphatase in mineralization process.

Authors:  Marcin Balcerzak; Eva Hamade; Le Zhang; Slawomir Pikula; Gérard Azzar; Jacqueline Radisson; Joanna Bandorowicz-Pikula; Rene Buchet
Journal:  Acta Biochim Pol       Date:  2003       Impact factor: 2.149

6.  Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment.

Authors:  Paul A Price; Jeffrey M Caputo; Matthew K Williamson
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

7.  The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation.

Authors:  Xiao-Dong Chen; Larry W Fisher; Pamela Gehron Robey; Marian F Young
Journal:  FASEB J       Date:  2004-06       Impact factor: 5.191

8.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

Authors:  Karen Staehling-Hampton; Sean Proll; Bryan W Paeper; Lei Zhao; Patrick Charmley; Analisa Brown; Jessica C Gardner; David Galas; Randall C Schatzman; Peter Beighton; Socrates Papapoulos; Herman Hamersma; Mary E Brunkow
Journal:  Am J Med Genet       Date:  2002-06-15

9.  Sclerostin binds and regulates the activity of cysteine-rich protein 61.

Authors:  Theodore A Craig; Resham Bhattacharya; Debabrata Mukhopadhyay; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2009-12-31       Impact factor: 3.575

10.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

View more
  13 in total

1.  Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.

Authors:  Y Asamiya; A Yajima; S Shimizu; S Otsubo; K Tsuchiya; K Nitta
Journal:  Osteoporos Int       Date:  2014-11-04       Impact factor: 4.507

Review 2.  Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2014-07-17       Impact factor: 4.507

Review 3.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

4.  Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.

Authors:  Zachary C Ryan; Hemamalini Ketha; Melissa S McNulty; Meghan McGee-Lawrence; Theodore A Craig; Joseph P Grande; Jennifer J Westendorf; Ravinder J Singh; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 5.  Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis.

Authors:  Rajiv Kumar; Volker Vallon
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

6.  Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Authors:  Rajendra Kedlaya; Shreya Veera; Daniel J Horan; Rachel E Moss; Ugur M Ayturk; Christina M Jacobsen; Margot E Bowen; Chris Paszty; Matthew L Warman; Alexander G Robling
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

7.  Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro.

Authors:  Cyril Thouverey; Joseph Caverzasio
Journal:  Bonekey Rep       Date:  2015-11-04

8.  Gene expression profiling of peri-implant healing of PLGA-Li+ implants suggests an activated Wnt signaling pathway in vivo.

Authors:  Anna Thorfve; Anna Bergstrand; Karin Ekström; Anders Lindahl; Peter Thomsen; Anette Larsson; Pentti Tengvall
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

9.  Impaired osteoblast differentiation in annexin A2- and -A5-deficient cells.

Authors:  Damian C Genetos; Alice Wong; Thomas J Weber; Norman J Karin; Clare E Yellowley
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

Review 10.  The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance.

Authors:  Gvantsa Kharaishvili; Dana Simkova; Katerina Bouchalova; Mariam Gachechiladze; Nato Narsia; Jan Bouchal
Journal:  Cancer Cell Int       Date:  2014-05-16       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.